Corcept targets $1.1B-$1.2B 2026 revenue as Lifyorli launch reaches 1,300 patients and relacorilant awaits Dec. 17 PDUFA
Corcept has set a revenue target of $1.1 billion to $1.2 billion for 2026, and the key positive factors include reaching Lifyorli patients and the upcoming relacorilant PDUFA schedule.
Given the strong revenue target for 2026 and the news surrounding new drug launches and PDUFA expectations, it is worth considering a buy. On July 30, the candlestick recorded an opening price of 112.0, a high of 122.21, a low of 104.75, and a closing price of 118.32, indicating strong volatility and an influx of buying momentum, leading to the decision to enter.
If the price is supported around the support level of 88, we will maintain our position, and when it breaks through the resistance level of 98 and the upward trend continues, we will take profits at the target price of $105.0. Conversely, if the stop-loss price line at the support level of $85.0 breaks down or if a clear downward trend emerges, we will respond with a stop-loss.
The CORT stock has a historical case that recorded a 27.3% return at the timestamp of 2026-07-31 03:26:24 with the same news. Similar successful cases include VEEE (2026-07-16 12:01:25, return 451.7%) and LRCX (2026-07-06 13:41:02, return 346.8%).
The actual return recorded was 27.3%, exceeding the forecasted return, as a stronger upward trend continued than expected. On July 30, the candle showed an opening price of 112.0, a high of 122.21, a low of 104.75, and a closing price of 118.32, confirming that strong volatility combined with positive news created a breakout above the resistance level.
Based on the results of this trade, I will consistently apply the method of using support and resistance levels during periods of strong volatility coinciding with positive announcements in future trades. Specifically, I will refine the execution of split responses and target price setting when price movements and news catalysts are both strongly active.